Hospira expands manufacturing capacity

- Last updated on GMT

Hospira, the hospital products company spun out of Abbott
Laboratories earlier this year, has acquired a manufacturing
facility that will help it grow its pharmaceutical injectable and
outsourcing business.

The facility is based in North Carolina and has been acquired from Fresenius Kabi, a subsidiary of German infusion specialist Fresenius. It includes a 100,000 square-foot facility and equipment and will provide Hospira with additional manufacturing capabilities to meet the industry demand for pharmaceutical injectables and intravenous solutions.

In addition, it will allow Hospira to grow its One 2 One injectable pharmaceutical outsourcing business, which focuses on contract manufacturing of emulsions and nutritional solutions

Hospira said that the transaction will not impact the results of its 2004 ongoing operations, but no additional financial details were disclosed.

The company was spun out of Abbott Laboratories early last month, with 14,000 employees, 14 manufacturing sites worldwide and an estimated $2.5 billion (€2.02bn) in annual sales, around 85 per cent of these coming from the US.

The company markets a wide range of injectable drugs, infusion sets, premixed intravenous solutions and prefilled syringes, as well as providing contract manufacture of drugs in vials, flexible containers, cartridges and prefilled syringes.

Related news

Related product

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers